vs
Beam Therapeutics Inc.（BEAM）与GDEV Inc.（GDEV）财务数据对比。点击上方公司名可切换其他公司
GDEV Inc.的季度营收约是Beam Therapeutics Inc.的1.1倍（$119.9M vs $114.1M），Beam Therapeutics Inc.净利率更高（214.1% vs 13.9%，领先200.2%），Beam Therapeutics Inc.同比增速更快（279.5% vs 13.3%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
GDEV Inc.是一家游戏娱乐控股公司，在纳斯达克上市，总部位于塞浦路斯利马索尔。该公司前身为2014年成立的游戏公司Nexters，2023年6月改组为控股集团，是欧洲前五的独立移动游戏企业，旗下拥有Nexters Studio、Cubic Games、Royal Ark、Game Gears、Light Hour Games等工作室，分支机构分布在塞浦路斯、亚美尼亚、哈萨克斯坦等地。
BEAM vs GDEV — 直观对比
营收规模更大
GDEV
是对方的1.1倍
$114.1M
营收增速更快
BEAM
高出266.2%
13.3%
净利率更高
BEAM
高出200.2%
13.9%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $119.9M |
| 净利润 | $244.3M | $16.6M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | 15.5% |
| 净利率 | 214.1% | 13.9% |
| 营收同比 | 279.5% | 13.3% |
| 净利润同比 | 370.4% | 13.0% |
| 每股收益（稀释后） | $2.53 | $0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMGDEV
| Q4 25 | $114.1M | — | ||
| Q2 25 | — | $119.9M | ||
| Q2 24 | — | $105.8M | ||
| Q4 23 | $316.2M | — | ||
| Q2 23 | — | $114.9M | ||
| Q2 22 | — | $125.8M |
净利润BEAMGDEV
| Q4 25 | $244.3M | — | ||
| Q2 25 | — | $16.6M | ||
| Q2 24 | — | $14.7M | ||
| Q4 23 | $142.8M | — | ||
| Q2 23 | — | $19.5M | ||
| Q2 22 | — | $29.3M |
营业利润率BEAMGDEV
| Q4 25 | -15.3% | — | ||
| Q2 25 | — | 15.5% | ||
| Q2 24 | — | 14.4% | ||
| Q4 23 | 42.0% | — | ||
| Q2 23 | — | 12.9% | ||
| Q2 22 | — | 34.4% |
净利率BEAMGDEV
| Q4 25 | 214.1% | — | ||
| Q2 25 | — | 13.9% | ||
| Q2 24 | — | 13.9% | ||
| Q4 23 | 45.2% | — | ||
| Q2 23 | — | 17.0% | ||
| Q2 22 | — | 23.3% |
每股收益（稀释后）BEAMGDEV
| Q4 25 | $2.53 | — | ||
| Q2 25 | — | $0.90 | ||
| Q2 24 | — | $0.81 | ||
| Q4 23 | $1.91 | — | ||
| Q2 23 | — | $0.99 | ||
| Q2 22 | — | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $41.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $-129.4M |
| 总资产 | $1.5B | $210.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMGDEV
| Q4 25 | $1.2B | — | ||
| Q2 25 | — | $41.6M | ||
| Q2 24 | — | $50.8M | ||
| Q4 23 | $1.2B | — | ||
| Q2 23 | — | $68.6M | ||
| Q2 22 | — | $91.4M |
股东权益BEAMGDEV
| Q4 25 | $1.2B | — | ||
| Q2 25 | — | $-129.4M | ||
| Q2 24 | — | $-118.7M | ||
| Q4 23 | $981.3M | — | ||
| Q2 23 | — | $-135.8M | ||
| Q2 22 | — | $-105.2M |
总资产BEAMGDEV
| Q4 25 | $1.5B | — | ||
| Q2 25 | — | $210.2M | ||
| Q2 24 | — | $282.8M | ||
| Q4 23 | $1.5B | — | ||
| Q2 23 | — | $302.2M | ||
| Q2 22 | — | $373.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | — |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMGDEV
| Q4 25 | $-83.3M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $135.1M | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $21.1M |
自由现金流BEAMGDEV
| Q4 25 | $-87.0M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $131.5M | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流率BEAMGDEV
| Q4 25 | -76.3% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 41.6% | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
资本支出强度BEAMGDEV
| Q4 25 | 3.3% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 1.1% | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金转化率BEAMGDEV
| Q4 25 | -0.34× | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 0.95× | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | 0.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
GDEV
暂无分部数据
